**1. Introduction**

130 Antihypertensive Drugs

[11] Gonzaga, CC; Passarelli Jr., O & Amodeo, C. (2009). Drugs interactions: angiotensin-

[12] Goodman, L.S & A. Gilman. (2010) As bases farmacológicas da terapêutica. 11 ed. LLBruntan; JS Lazo;KL Parker. McGrawl-hill, Rio de Janeiro: Guanabara Koogan. Goodman, LS & Gilman, A. (11 ed). (2010). *As bases farmacológicas da* 

[13] Houston, MC. (1991) Nonsteroidal anti-inflammatory drugs and antihypertensives. The American Journal of *Medicine*. v. 90 n.5, Suppl. 1, p. S42-47, *ISSN 0002-9343.*  [14] Ishiguro, C; Fujita, T; Omori, T; Fujii, Y; Mayama, T & Sato, T. (2008).Assessing the

[15] Klasco RK (editor): DRUG-REAX® System. Thomson MICROMEDEX, Greenwood

[16] Kirk JK & Johnson SH. (1995). Safe Discontinuation of Antihypertensive Therapy.

[17] Lieberman, P. (1998) Anaphylaxis and Anaphylactoid Reactions. In: *Allergy – principles* 

[18] Mark, CH. (1991).Nonsteroidal anti-inflammatory drugs and antihypertensives. *The American Journal of Medicine*, v. 90 n.5, Suppl. 1, p. S42-47, ISSN 0002-9343*.*  [19] Matos, VTG; Vasconcelos, EF; Amaral, MS & Toffoli-Kadri, MC. (2009). Avaliação das

[20] Meneses, A; Monteiro HS. (2000). Prevalência de interações medicamentosas "droga-

[21] Ortega, TM; Feldman, EC; Nelson, RW; Willits, N & Cowgill, LD. (1996) Sistemic

[22] Plavnik, FL. (2002).Hipertensão arterial induzida por drogas: como detectar e tratar.

[23] Pitrowsky, M; Shinotsuka CR; Soares M & Salluh JIF. (2009). Controle glicêmico em

[24] Sierra, P; Castillo, J; Gómez, M; Sorribes, V; Monterde, J & Castaño J. (1997). Potential

[25] Trato, DS. (2005). *Drug interactions facts.* St Louis: Facts and Comparisons. ISBN

*Revista Brasileira Hipertensão*. v. 9, n.2, p. 185-191, ISSN *1519-7522*.

*Revista Brasileira Hipertensão*. v.16, n.4, p.221-225, ISSN 1519-7522.

*terapêutica.*McGrawl-hill, ISBN 85-7726-001-1, Rio de Janeiro.

*Archives Family Medicine*. v. n.4, p.266-270, ISSN 1063-3987*.*

*Brasileira Terapia Intensiva*.v. 12, n.1, p.4-7, ISSN 0103-507X.

n.3,p. 119-124, ISSN 1349-9092 .

Village, Colorado. Accessed in Oct 2011.

WW, eds., 5 ed, Mosby, Saint Louis.

n. 10, p.1724-1729, ISSN 0003-1488.

*Intensiva*. v.21, n.3, p. 310-314, ISSN 0103-507*X.* 

*Reanimación*. v. 44, n.10 p.383-7, ISSN *0034-9356.* 

0326-2383.

157439195X

converting enzyme inhibitors, angiotensin II-receptor antagonists, renin inhibitors.

Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database. *Journal of Epidemiology*. v.18,

*and pratice* Middleton E; Ellis EF; Reed CE; Adkinson NF; Yunginger JW & Busse

Interações Medicamentosas em Prescrições Hospitalares de Pacientes Sob Uso de Anti-Hipertensivos. *Latin American Journal of Pharmacy*. v. 28, n. 4, p. 501-6, ISSN:

droga" potenciais em duas UTIs (pública X privada) de Fortaleza, Brasil. *Revista* 

arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. *Journal* of the *American Veterinary Medical Association*, v. 209,

terapia intensiva 2009: sem sustos e sem surpresas. *Revista Brasileira Terapia* 

and real drug interactions in critical care patients. *Revista Española Anestesiologia y* 

This chapter is drawing out the patterns and evidences for the use of antihypertensive medicines in general and in primary health care settings in particular. It presents the overview of the recent advances in clinical effectiveness of the antihypertensive medicines, but also document the implication for management of hypertension in low level health facilities. The discussions are based on the new evidences from clinical practice, reviews and meta-analysis studies.

The chapter as whole is written from a comprehensive health care system development rather than from a purely medicines description perspective. Finally the authors do not intend to substitute the students or prescribers vademecum or medicines' handbooks but providing an update in their daily questions when comes the issue of whom, what (and with what) to treat – as far as arterial hypertension is concerned, in primary health care settings.
